OBJECTIVES: To study the presence of HIV-1 group O infection among HIV-infected people in Cameroon and to further characterize the HIV-1 group O infections. DESIGN AND METHODS: During a 2-year survey (1994-1995), all samples tested positive in screening methods in the National Reference and Public Health Laboratory, Centre Pasteur, Yaoundé, Cameroon were identified as HIV-1 group M, HIV-1 group O or HIV-2 by using a serological algorithm. HIV-1 group M and HIV-1 group O were distinguished on the basis of competitive enzyme-linked immunosorbent assay (ELISA) reactivity against gp41 group M recombinant protein. HIV-1 group O infections were confirmed by using group O-specific V3 synthetic peptides. HIV-1 group O strains were isolated by lymphocyte cocultures, proviral DNA was amplified with specific primers, and sequencing was performed on the C2V3 and gag regions. RESULTS: Of the 8,331 screened samples, 3,193 were HIV-reactive, 2,376 (74%) of which were considered to belong to group M. The 817 (26%) that had reacted poorly or not at all against group M gp41 were further characterized: 10 were confirmed as HIV-2 and 82 as HIV-1 group O, the others being indeterminate (n = 285) or negative (n = 440). The frequency of group O relative to group M ranged from 1% in Far North province to 6.3% in the capital. There was no difference in sex, age or frequency of clinical manifestations between group M and group O infections. Group O infection was confirmed in a subset of cases by polymerase chain reaction (n = 14), with perfect concordance. Sequencing and phylogenetic analyses confirmed the high variability inside group O. CONCLUSIONS: Group O and group M epidemiological patterns are known to be similar so the reason for the lower prevalence of group O remains to be found. The wide distribution of group O infection in all Cameroonian provinces underlines the importance of further characterizing the epidemic spread and diffusion of this group.
OBJECTIVES: To study the presence of HIV-1 group Oinfection among HIV-infected people in Cameroon and to further characterize the HIV-1 group O infections. DESIGN AND METHODS: During a 2-year survey (1994-1995), all samples tested positive in screening methods in the National Reference and Public Health Laboratory, Centre Pasteur, Yaoundé, Cameroon were identified as HIV-1 group M, HIV-1 group O or HIV-2 by using a serological algorithm. HIV-1 group M and HIV-1 group O were distinguished on the basis of competitive enzyme-linked immunosorbent assay (ELISA) reactivity against gp41 group M recombinant protein. HIV-1 group O infections were confirmed by using group O-specific V3 synthetic peptides. HIV-1 group O strains were isolated by lymphocyte cocultures, proviral DNA was amplified with specific primers, and sequencing was performed on the C2V3 and gag regions. RESULTS: Of the 8,331 screened samples, 3,193 were HIV-reactive, 2,376 (74%) of which were considered to belong to group M. The 817 (26%) that had reacted poorly or not at all against group M gp41 were further characterized: 10 were confirmed as HIV-2 and 82 as HIV-1 group O, the others being indeterminate (n = 285) or negative (n = 440). The frequency of group O relative to group M ranged from 1% in Far North province to 6.3% in the capital. There was no difference in sex, age or frequency of clinical manifestations between group M and group O infections. Group O infection was confirmed in a subset of cases by polymerase chain reaction (n = 14), with perfect concordance. Sequencing and phylogenetic analyses confirmed the high variability inside group O. CONCLUSIONS: Group O and group M epidemiological patterns are known to be similar so the reason for the lower prevalence of group O remains to be found. The wide distribution of group O infection in all Cameroonian provinces underlines the importance of further characterizing the epidemic spread and diffusion of this group.
Authors: Philippe Lemey; Oliver G Pybus; Andrew Rambaut; Alexei J Drummond; David L Robertson; Pierre Roques; Michael Worobey; Anne-Mieke Vandamme Journal: Genetics Date: 2004-07 Impact factor: 4.562
Authors: S Corbet; M C Müller-Trutwin; P Versmisse; S Delarue; A Ayouba; J Lewis; S Brunak; P Martin; F Brun-Vezinet; F Simon; F Barre-Sinoussi; P Mauclere Journal: J Virol Date: 2000-01 Impact factor: 5.103
Authors: Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts Journal: AIDS Res Hum Retroviruses Date: 2016-03-16 Impact factor: 2.205
Authors: S Souquière; F Bibollet-Ruche; D L Robertson; M Makuwa; C Apetrei; R Onanga; C Kornfeld; J C Plantier; F Gao; K Abernethy; L J White; W Karesh; P Telfer; E J Wickings; P Mauclère; P A Marx; F Barré-Sinoussi; B H Hahn; M C Müller-Trutwin; F Simon Journal: J Virol Date: 2001-08 Impact factor: 5.103
Authors: S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch Journal: Infection Date: 2013-12-06 Impact factor: 3.553
Authors: M Peeters; F Liegeois; N Torimiro; A Bourgeois; E Mpoudi; L Vergne; E Saman; E Delaporte; S Saragosti Journal: J Virol Date: 1999-09 Impact factor: 5.103
Authors: Frederic Bibollet-Ruche; Anke Heigele; Brandon F Keele; Juliet L Easlick; Julie M Decker; Jun Takehisa; Gerald Learn; Paul M Sharp; Beatrice H Hahn; Frank Kirchhoff Journal: J Clin Invest Date: 2012-04-16 Impact factor: 14.808